Oxurion NV announced top-line results from Part A of its Phase II trial of THR-687, an integrin antagonist, for the treatment of DME.
[Oxurion NV]
Home Newsletters Endothelial Cell News Oxurion Announces Top-Line Results from Part A of Phase II INTEGRAL Trial...
